News stories about AnaptysBio (NASDAQ:ANAB) have been trending somewhat positive on Sunday, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. AnaptysBio earned a daily sentiment score of 0.16 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 46.1502199974646 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Here are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:

A number of research analysts have weighed in on the company. Stifel Nicolaus raised their price objective on AnaptysBio from $30.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, May 2nd. Zacks Investment Research lowered AnaptysBio from a “hold” rating to a “sell” rating in a report on Tuesday, April 25th. Robert W. Baird assumed coverage on AnaptysBio in a report on Monday, July 10th. They issued an “outperform” rating and a $36.00 price objective on the stock. Finally, Credit Suisse Group restated an “outperform” rating and issued a $34.00 price objective on shares of AnaptysBio in a report on Tuesday, April 18th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. AnaptysBio currently has an average rating of “Buy” and an average price target of $35.60.

AnaptysBio (NASDAQ ANAB) traded up 2.37% on Friday, hitting $21.99. The stock had a trading volume of 290,444 shares. AnaptysBio has a one year low of $15.17 and a one year high of $30.71. The stock’s market cap is $447.32 million. The stock’s 50 day moving average is $24.81 and its 200 day moving average is $24.47.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.42) by $0.29. The company had revenue of $7 million during the quarter, compared to analysts’ expectations of $3.45 million. Analysts anticipate that AnaptysBio will post ($2.48) earnings per share for the current year.

In other news, major shareholder Holdings A/S Novo sold 491,294 shares of the company’s stock in a transaction on Monday, August 7th. The stock was sold at an average price of $21.12, for a total value of $10,376,129.28. Following the sale, the insider now directly owns 2,952,527 shares in the company, valued at $62,357,370.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Ventures Vii L. P. Avalon sold 37,040 shares of the company’s stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $24.35, for a total value of $901,924.00. The disclosure for this sale can be found here. Insiders sold 599,040 shares of company stock worth $12,926,210 over the last 90 days.

ILLEGAL ACTIVITY WARNING: This story was originally published by Daily Political and is owned by of Daily Political. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at

AnaptysBio Company Profile

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with's FREE daily email newsletter.